27 November 2013 - NICE is calling on the pharmaceutical company Norgine to provide more information on its drug Xifaxan (rifaximin) to treat a brain disease caused by liver failure. NICE is appraising rifaximin as a treatment for the condition known as hepatic encephalopathy. In draft guidance published for consultation, NICE has asked for more data to be submitted by the manufacturer.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICESeeksMoreInfoTreatmentPotentiallySeriousLiverCondition.jsp